Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.

C MartineauB FlouriéP WilsT VaysseR AltweggAnthony BuissonA AmiotG Pineton de ChambrunV AbitbolM FumeryX HébuterneS ViennotD LaharieL BeaugerieS NanceyH Sokolnull null

Published in: Alimentary pharmacology & therapeutics (2017)

After failure of infliximab or adalimumab for Crohn's disease, golimumab was safe and seemed beneficial in half of the patients.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
rheumatoid arthritis
ankylosing spondylitis
prognostic factors
systemic lupus erythematosus
patient reported